Cite
Yamashita S, Kawakami Y, Sato H, et al. Erratum to 'Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice' [Eur. J. Pharmacol. 859 (2019) 172521]. Eur J Pharmacol. 2019;862:172633doi: 10.1016/j.ejphar.2019.172633.
Yamashita, S., Kawakami, Y., Sato, H., Sugitani, S., Goto, M., & Kato, N. (2019). Erratum to 'Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice' [Eur. J. Pharmacol. 859 (2019) 172521]. European journal of pharmacology, 862172633. https://doi.org/10.1016/j.ejphar.2019.172633
Yamashita, Satoko, et al. "Erratum to 'Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice' [Eur. J. Pharmacol. 859 (2019) 172521]." European journal of pharmacology vol. 862 (2019): 172633. doi: https://doi.org/10.1016/j.ejphar.2019.172633
Yamashita S, Kawakami Y, Sato H, Sugitani S, Goto M, Kato N. Erratum to 'Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice' [Eur. J. Pharmacol. 859 (2019) 172521]. Eur J Pharmacol. 2019 Nov 05;862:172633. doi: 10.1016/j.ejphar.2019.172633. Epub 2019 Sep 10. PMID: 31519353.
Copy
Download .nbib